



Illumina Opens New State of the Art Enzyme Production Facility in Madison

General Capital Group, a real estate development company specializing in life sciences development and other complex build-to-suits, recently celebrated Illumina’s new space - a build-to-suit R&D, production lab and office facility adjacent to the University of Wisconsin’s University Research Park in Madison, Wisconsin. A select group of community members, including UW-Madison researchers, biotech leaders, and project team members joined in the celebration.

“The opening of 524 Genomic Drive represents Illumina’s significant investment in Madison, an important site in our global business and manufacturing strategy,” said Nick Caruccio, Vice President of Manufacturing at Illumina. “The expansion gives us the capability to collaborate and innovate across all components of Illumina consumables business. This enables the company to develop and incorporate new enzymes that drive enhanced performance and improve the overall sequencing experience.”

This beautiful state-of-the-art facility is already helping Illumina's ongoing efforts to recruit and retain a high-quality workforce in Madison's competitive hiring environment.



Illumina Virtual Tour: https://www.illumina.com/company/video-hub/PbGLZEIS_u8.html.

Global genomics leader Illumina provides innovative sequencing and array technologies that are fueling groundbreaking advancements in life sciences research, translational and consumer genomics, and molecular diagnostics. Advances in genomics are triggering a fundamental shift in healthcare and beyond, and Illumina provides innovative, flexible and scalable solutions that are making studies possible that were unimaginable just a few years ago. More than 90% of genetic sequencing worldwide is done on Illumina's sequencers.

Due to the rapid growth in Madison operations, Illumina was working out of several undersized and dated facilities. To support continued growth, the Company created a highly efficient facility to optimize its reagent and enzyme production, consolidate manufacturing and office activities, and maximize collaboration. Illumina hired General Capital Group to spearhead the planning, municipal entitlements, design, construction and financing of its new 133,000 square foot building.

General Capital partnered with JH Findorff, the general contractor, project architect Kahler Slater, lab designer Flad Architects, and mechanical engineer EXP to create a facility that provides the necessary environment to manufacture enzymes and reagents. These components are used by Illumina's DNA sequencers and facilitate reading DNA strands at large scale. The building houses space for fermentation, purification, QA/QC, and bulk filling, as well as R&D and sequencing labs. A warehouse supports the shipping and receiving of bulk raw

materials, cold storage, and shipping of product to other Illumina sites. The building also contains Class A office space with an amenities package including a dining area, fitness center, training room and multiple conference rooms in a variety of configurations.

The development team worked closely with Illumina, ensuring that countless details were carefully evaluated and fully coordinated. This collaborative process resulted in a project that dramatically improves the efficiency of Illumina's Madison operations and provides much better opportunities for creative interaction among its employees. By delivering the complex project on time and significantly under budget, the team met Illumina's imperatives for speed to market and budgetary control. General Capital acquired additional land so that Illumina has the ability to plan for future growth and expand onsite. This affords the Company an opportunity to leverage its onsite facility and human resources to maximize the efficiency of its next project.